Florida Resident Pleads Guilty To Fraudulent Shipments Of Synthetic Drugs From Lab In Stockton
Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

  • Who We Are
    • About
    • Mission
    • Leadership
    • History
    • Divisions
      • Domestic Divisions
      • Foreign Divisions
      • Operational Divisions
    • DEA Museum
    • Wall of Honor
    • Contact Us
      • Submit a Tip
      • Extortion Scam
      • Public Affairs
      • Social Media Directory
  • What We Do
    • Forensic Sciences
      • GUARDS
      • Forensic Sciences Policy
      • Forensic Science Organizations
      • Forensic Science Contact
    • Law Enforcement
      • DEA Office of Training
        • Office of Training Programs
      • El Paso Intelligence Center (EPIC)
      • Intelligence
      • Operations
        • Administrative Law Judges
        • DEA Asset Forfeiture
        • Domestic Cannabis Suppression / Eradication Program
        • HIDTA
        • OCDETF
    • Education and Prevention
      • Family Summit
      • Red Ribbon
      • Kiki and the History of Red Ribbon Week
      • Red Ribbon Toolkit - Resources For Your Community
      • DEA’s Family Summit
      • Operation Engage
      • Community Outreach
      • Just Think Twice
      • Campus Drug Prevention
      • Get Smart About Drugs
      • Operation Prevention
    • Drug Information
      • Drug Policy
      • Drug Scheduling
      • The Controlled Substances Act
    • News
      • Alerts
      • Press Releases
      • Most Wanted Fugitives
        • All Fugitives
      • Stories
      • Events
      • Speeches
      • Testimony
    • Campaigns
      • One Pill Can Kill
        • Senior Citizens
        • Partner Toolbox
        • Social Media Campaign
      • DEA National Prescription Drug Take Back Day
  • Careers
    • Special Agent
      • Special Agent FAQs
    • Diversion Investigator
      • Diversion Investigator Job Announcement
    • Intelligence Research Specialist
      • Intelligence Research Specialist Job Announcements
      • Intelligence Research Specialists FAQs
      • Schedule A Hiring Authority: Intelligence Research Specialist
    • Forensic Sciences Careers
    • Professional & Administrative Careers
    • Student & Entry Level Careers
    • Employment Eligibility
    • How to Apply
      • How To Claim Veterans' Preference
      • Priority Consideration
      • Benefits
      • Veterans and People With Disabilities
      • Operation Warfighter
  • Resources
    • Cartels
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Data and Statistics
      • Domestic Arrests
      • Staffing and Budget
    • FOIA
      • About FOIA
      • Contact DEA FOIA
      • Make a Request
      • What Happens After Making a Request
      • Requester Categories
      • Fees Charged
      • Fee Waiver
      • FOIA FAQ
      • FOIA Logs and Reports
      • FOIA Library
      • Additional FOIA Links
      • FOIA Exemptions
      • What Are Exclusions?
      • Privacy Act
      • Privacy Act Exemptions
      • Privacy Impact Assessment and Management Information Systems
    • Publications
    • Media Galleries
    • Victim Witness Assistance Program
      • Victim Witness Assistance Program Resources
      • Human Trafficking Prevention

United States Drug Enforcement Administration

  • Get Updates
  • Scam Alert
  • Full Menu
  • English
  • Español

Main Menu

Explore DEA
  • Who We Are
    • About
    • Mission
    • Leadership
    • History
    • Divisions
    • DEA Museum
    • Wall of Honor
    • Contact Us
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Education and Prevention
    • Drug Information
    • News
    • Campaigns
  • Careers
    • Special Agent
    • Diversion Investigator
    • Intelligence Research Specialist
    • Forensic Sciences Careers
    • Professional & Administrative Careers
    • Student & Entry Level Careers
    • Employment Eligibility
    • How to Apply
  • Resources
    • Cartels
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Data and Statistics
    • FOIA
    • Publications
    • Media Galleries
    • Victim Witness Assistance Program
  • Submit A Tip

Breadcrumb

  • Home
  • Florida Resident Pleads Guilty To Fraudulent Shipments Of Synthetic Drugs From Lab In Stockton

Florida Resident Pleads Guilty To Fraudulent Shipments Of Synthetic Drugs From Lab In Stockton

May 09, 2016
|
Share Article
|
Download Press Release
For Immediate Release
Contact: Akilah Johnson
Phone Number: (415) 436-7994

FRESNO, Calif. - Timothy New, 33, of Pensacola, Florida, pleaded guilty today to shipping in interstate commerce, with intent to defraud, misbranded synthetic drugs, commonly known as “spice,” Acting United States Attorney Philip A. Talbert and Drug Enforcement Administration Special Agent in Charge John J. Martin announced.

According to court documents, between September 2012 and May 2103, New and his co‑defendants utilized a manufacturing and distribution operation at a processing lab in Stockton to ship at least 24 tons of misbranded smokeable synthetic cannabinoids that contained the synthetic drugs AM-2201 and XLR11 to smoke shops and retail outlets throughout the United States. They generated in excess of $33 million as a result of the fraudulent sales.

Operating under the guise of legitimacy by companies called Zencense Incense Works LLC, ZenBio LLC, and Biozen LLC, New and his co-defendants received falsely invoiced raw synthetic cannabinoids from China that they used to manufacture and distribute as smokeable synthetic cannabinoids. The drugs were sold under the brand names Bizarro, Orgazmo, Headhunter, Defcon, Neutronium, Sonic Zero, Sonic Boom, Sonic Blast, Shockwave, Hampster, and Posh. To evade detection by federal law enforcement authorities, New and his co-defendants deliberately misbranded and marketed their product as “potpourri” or “herbal incense” that they claimed was “not for human consumption,” but fully intended to be used as a narcotic. New and his co-defendants distributed the drugs to the Stuffed Pipe smoke shops located throughout the Central Valley of California, as well as to numerous other retail establishments throughout the United States.

At the time of the illicit enterprise, AM-2201 was a Schedule I controlled substance and XLR11 was a controlled substance analogue that was publically noticed for scheduling in April, 2013, and was placed under Schedule I as a controlled substance in May, 2013.

Public health and law enforcement agencies have seen the emergence of synthetic drug use. State and local public health departments note that synthetic cannabinoids cause serious adverse health effects, including agitation, anxiety, nausea, vomiting, tachycardia, elevated blood pressure, tremor, seizures, hallucinations, and paranoid behavior. DEA scheduled XLR11 based, in part, on findings of the Center for Disease Control and Prevention that the drug causes kidney damage.

This case is the product of an Organized Crime Drug Enforcement Task (OCDETF) investigation by the Drug Enforcement Administration, Internal Revenue Service-Criminal Investigation, and the U.S. Immigration and Customs Enforcement’(ICE) Homeland Security (HSI), with assistance from the Food and Drug Administration and the Fresno County Sheriff’s Office. Assistant United States Attorney Karen A. Escobar is prosecuting the case.

The OCDETF Program was established in 1982 to mount a comprehensive attack against organized drug traffickers. Today, the OCDETF Program is the centerpiece of the United States Attorney General's drug strategy to reduce the availability of drugs by disrupting and dismantling major drug trafficking organizations and money laundering organizations and related criminal enterprises. This OCDETF investigation was also part of a nationwide law enforcement effort coordinated by the DEA’s Special Operations Division.

New is scheduled for sentencing on August 1, 2016, by United States District Judge Dale A. Drozd. He faces a maximum statutory penalty of three years in prison and a $250,000 fine, or twice the gross gain from the crime. The actual sentence, however, will be determined at the discretion of the court after consideration of any applicable statutory factors and the Federal Sentencing Guidelines, which take into account a number of variables.
 
Co-defendants Douglas Jason Way, 41, of Evanston, Illinois, Timothy Ortiz, 45, of Waukegan, Illinois, and Natalie Middleton, 28, of Clovis, California, have entered not guilty pleas and are next scheduled to appear in federal court in September. They are charged with drug and money laundering offenses, in addition to the misbranding charge, and face a maximum penalty of 20 years in prison and a $10 million fine. The charges against them are only allegations; Way, Ortiz, and Middleton are presumed innocent until and unless proven guilty beyond a reasonable doubt.

Download Press Release
###
US Department of Justice - Drug Enforcement Administration

Drug Enforcement Administration

Bob P. Beris, Special Agent in Charge - San Francisco
@DEASanFrancisco
  • Facebook
  • X
  • Email
  • Who We Are
    • About
    • Domestic Divisions
    • Foreign Offices
    • Contact Us
    • DEA Museum
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Drug Prevention
    • Diversion Control Division
    • News
  • Careers
    • Special Agent
    • Diversion Investigator
    • Forensic Sciences
    • Intelligence Research Specialist
    • How to Apply
  • Resources
    • Drug Information
    • Employee Assistance Program
    • FOIA
    • Publications
    • Media Galleries
    • VWAP
  • Doing Business
    with the DEA
    • Overview
    • Current Vendors
    • Prospective Vendors
    • Security Clauses
    • Security Forms
    • Small Business Program
    • Vendor Engagement Request
  • Policies
    • Accessibility & Policy
    • Legal Policies & Disclaimers
    • No FEAR Act
    • Privacy Policy
    • U.S. Department of Justice EEO Policy
    • USA.gov
    • Whistleblower Protection
    • Your Rights as a Federal Employee

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook X LinkedIn Instagram

DEA Contact Center

(202) 307-1000
Contact the Webmaster